Leflunomide Tablet
Product Images NDC 62135-794

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 62135-794). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Leflunomide 10mg 30s Label)

Leflunomide 10 mg tablets label from Chartwell RX, LLC. The packaging is for 30 oral tablets, marked Rx Only. It includes storage instructions, warnings to keep out of reach of children, and a barcode with NDC 62135-793-30.*

FDA Label Image

Image Description (Leflunomide 20mg 30s Label)

Label for Leflunomide 20 mg tablets by Chartwell RX, LLC. The label displays the product name Leflunomide Tablets USP, strength 20 mg, quantity 30 tablets, and indicates prescription use (Rx Only). It includes storage and handling instructions and a barcode.*

FDA Label Image

"image Description" (Leflunomide Fig 1)

A bar chart titled '% ACR 20 Responder at Endpoint' comparing response percentages for Leflunomide, Methotrexate, Placebo, and Sulfasalazine across three clinical trials of 6 to 12 months. The chart shows percentage response outcomes by treatment group for each trial, with Leflunomide, Methotrexate, Placebo, and Sulfasalazine indicated by different bar patterns.*

FDA Label Image

"image Description" (Leflunomide Fig 2)

A line chart titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders over a 12-month period. The x-axis represents time in months (0, 3, 6, 9, 12), and the y-axis shows the percent of responders ranging from -10 to 70%. Three treatment groups are plotted: PL (placebo) with open circles, MTX (methotrexate) with open squares and dashed lines, and LEF (leflunomide) with solid black triangles and a solid line. Leflunomide shows the highest percentage of responders throughout the trial compared to placebo and methotrexate. A note at the bottom indicates 'Last Observation Carried Forward.'*

FDA Label Image

"image Description" (Leflunomide Fig 3)

A bar chart titled "Change in Sharp Score" showing data from three clinical trials at 6 and 12 months. The y-axis represents progression with values ranging from -10 to 8. Bars represent different groups labeled L, M, P, and S with corresponding scores for each trial period, illustrating variations in Sharp Score changes over time.*

FDA Label Image

"image Description" (Leflunomide Fig 4)

A bar graph titled 'Change in Functional Ability Measure' showing results from three trials over different time periods (12 months, 6 months, 12 months). The y-axis represents improvement values ranging from -0.6 to 0.2. Each trial compares data labeled L, M, and P with bars indicating varying degrees of negative improvement values in functional ability.*

FDA Label Image

"image Description" (Leflunomide Structure 2)

Chemical structure diagram labeled as A77 1726 (teriflunomide), depicting the molecular structure related to leflunomide, showing rings, functional groups, and chemical bonds including trifluoromethyl, amide, hydroxyl, and nitrile groups.*

FDA Label Image

"image Description" (Leflunomide Structure)

Chemical structure diagram of Leflunomide, showing its molecular framework with key groups including a trifluoromethyl-substituted aromatic ring and an amide linkage.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.